HighLife secures $90M for US heart valve trial and European growth
HighLife has raised $90 million to expand its transcatheter mitral valve replacement (TMVR) business in Europe and begin a pivotal study in the US. The funding will support commercial operations abroad while advancing clinical trials domestically.
Sources: ventureburn.com
“This funding round highlights the growing investor confidence in TMVR, a space that has seen slower adoption than TAVR but is now attracting significant capital.”
What it means
TMVR has lagged behind transcatheter aortic valve replacement (TAVR) in commercialization, but recent funding suggests momentum is building. HighLife’s ability to balance European expansion with US trials could set a template for other medtech startups targeting dual-market growth. Success in the US study will be critical for broader adoption.
Read the original reporting
This is a short summary. The outlets below did the reporting.
This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.